How to move to post-Brexit pharmacovigilance effortlessly and efficiently

Nov 27, 2020

In 2021 the United Kingdom is moving to its post-Brexit life with new processes, procedures, and laws everywhere, including clinical trials and pharmacovigilance. This piece we dedicate to a simple question – how to move to post-Brexit pharmacovigilance effortlessly and efficiently.

All information in this article is based on Updated guidance on pharmacovigilance procedures published by Medicines & Healthcare products Regulatory Agency, last updated 27 October 2020.

Let’s dive into updated submissions data:

When: From 1 January 2021

Who: Marketing Authorisation Holders (MAH) of medicines authorised in Great Britain

Where to submit: to the MHRA

What to submit: all pharmacovigilance data, including

  • UK and non-UK Individual Case Safety Reports (ICSRs)
  • Periodic Safety Update Reports (PSURs)
  • Risk Management Plans (RMPs)
  • Post-Authorisation Safety Studies (PASS) protocols and final study reports

Flex Databases Pharmacovigilance is here to help you with the new MHRA Gateway submissions of ICSRs.

Submitting Individual Case Safety Reports

As the MHRA states, “We will require submission of all UK (including NI) ICSRs (serious and non-serious) and serious ICSRs from other countries via the new MHRA Gateway or/ICSR Submissions portal which have been developed.”

How we proceed:

The MHRA recommends registering for submissions “as early as possible”.

Move to compliant PV system within a month before regulation changes? We say let’s do it!

To start moving to post-Brexit pharmacovigilance, request a quote or learn more request a demo via the button on top of the page, or send us an e-mail to!

More about Pharmacovigilance

Manage multi-lingual cases within a single instance with Flex Databases Pharmacovigilance

With Flex Databases Pharmacovigilance, you’ll only need one case, and you can add as many languages to it as you want.

Learn more
Three big questions AI helps to answer in drug development process

By automating processes, reducing human error, and improving decision-making, AI can help make clinical trials more efficient, effective, and safe.

Learn more
Clinergy Health Research selects Flex Databases Pharmacovigilance as cost-effective and easy to integrate solution

Clinergy Health Research selects Flex Databases Pharmacovigilance as cost-effective and easy to integrate solution

Learn more
Flex Databases recognised as one of top-10 Pharmacovigilance providers in the UK & Europe

This September, Pharma Tech Outlook included Flex Databases in Top-10 Pharmacovigilance solutions providers in the UK & Europe.

Learn more

Get in touch to discuss compliance, implementation, demos, pricing

We are here for all of your questions! Tell us more about yourself and we will organize a tailored live demo to show how you can power up your clinical trials processes with Flex Databases.